Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.

Journal of medicinal chemistry - 23 Apr 1998

McKie J H, Douglas K T, Chan C, Roser S A, Yates R, Read M, Hyde J E, Dascombe M J, Yuthavong Y, Sirawaraporn W

Abstract excerpt

Pyrimethamine acts by selectively inhibiting malarial dihydrofolate reductase-thymidylate synthase (DHFR-TS). Resistance in the most important human parasite, Plasmodium falciparum, initially results from an S108N mutation in the DHFR domain, with additional mutation (most commonly C59R or N51I o...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimalarials
Share to Drug Resistance
Share to Mice

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multienzyme Complexes

Share to Mutation

Share to Plasmodium falciparum

Share to Recombinant Proteins

Share to Tetrahydrofolate Dehydrogenase

Source

Identifiers

PMID: 9554869
DOI: 10.1021/jm970845u

Genes

DHFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-9554869-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.PMID 9554869Read ↗

Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised targetSemantic proximity Read ↗

Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?Semantic proximity Read ↗

Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria.Semantic proximity Read ↗

In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.Semantic proximity Read ↗

Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays.Semantic proximity Read ↗

Understanding the Pyrimethamine Drug Resistance Mechanism via Combined Molecular Dynamics and Dynamic Residue Network Analysis.Semantic proximity Read ↗

Stepwise acquisition of pyrimethamine resistance in the malaria parasite.Semantic proximity Read ↗

Pyrimethamine resistant mutations in Plasmodium falciparum.Semantic proximity Read ↗

Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli.Semantic proximity Read ↗

Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.Semantic proximity Read ↗

Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors.Semantic proximity Read ↗

In Vitro Resistance Selections for Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered GrowthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.